Back to top
more

Mallinckrodt public limited company (MNK)

(Delayed Data from NYSE)

$16.14 USD

16.14
1,972,598

+0.44 (2.80%)

Updated May 3, 2019 04:02 PM ET

After-Market: $16.14 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Options Traders Betting on a Big Move in Mallinckrodt (MNK) Stock?

by Zacks Equity Research

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

Mallinckrodt Completes NDA Submission for Kidney Failure Drug

by Zacks Equity Research

Mallinckrodt (MNK) nears approval of its kidney failure candidate, terlipressin, with the completion of rolling submission of an NDA for the same.

Kinjel Shah headshot

Coronavirus Drug Development Efforts Pick Up Amid Sell-Off

by Kinjel Shah

Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.

Mallinckrodt Up on New York's Support for Opioid Settlement

by Zacks Equity Research

Mallinckrodt's (MNK) proposed global opioid settlement receives support from New York State Attorney General, taking the total support count to 48 states and territories.

Are Options Traders Betting on a Big Move in Mallinckrodt (MNK) Stock?

by Zacks Equity Research

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

Endo's (ENDP) Earnings & Revenues Trump Estimates in Q4

by Zacks Equity Research

Endo (ENDP) earnings and sales beat estimates in the fourth quarter but witness year-over-year declines.

Mallinckrodt Gains on Opioid Settlement, Beats on Q4 Earnings

by Zacks Equity Research

Mallinckrodt (MNK) signs a $1.6-billion agreement for its ongoing opioid litigation and reports better-than-expected Q4 results.

Mallinckrodt (MNK) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Mallinckrodt (MNK) delivered earnings and revenue surprises of 17.07% and 3.99%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Why Mallinckrodt (MNK) Might Surprise This Earnings Season?

by Zacks Equity Research

Mallinckrodt (MNK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Mallinckrodt (MNK) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Implied Volatility Surging for Mallinckrodt (MNK) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

Should Value Investors Consider Mallinckrodt (MNK) Stock?

by Zacks Equity Research

Mallinckrodt (MNK) stock may be a good choice for value-oriented investors right now from multiple angles.

J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge

by Zacks Equity Research

A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.

Endo Up on Opioid Abuse Settlement Agreement With Oklahoma

by Zacks Equity Research

Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.

Indrajit Bandyopadhyay headshot

Will J&J be Able to Overcome Its Legal Troubles in 2020?

by Indrajit Bandyopadhyay

Here we discuss the growth potential of J&J's (JNJ) stock in 2020.

Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis

by Zacks Equity Research

Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.

Implied Volatility Surging for Mallinckrodt (MNK) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

Mallinckrodt (MNK) Up 28.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders

by Zacks Equity Research

J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.

Kinjel Shah headshot

Fed Reportedly Opens Criminal Investigation on Opioid Makers

by Kinjel Shah

Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.

Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA

by Zacks Equity Research

The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.

Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss

by Zacks Equity Research

Mallinckrodt (MNK) misses on sales but beats on earnings in the third quarter of 2019.

Mallinckrodt (MNK) Q3 Earnings Beat Estimates

by Zacks Equity Research

Mallinckrodt (MNK) delivered earnings and revenue surprises of 4.55% and -3.71%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Is a Beat in the Cards for Mallinckrodt (MNK) in Q3 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q3 results.

Mylan (MYL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers, when Mylan (MYL) reports Q3 results along with updates on merger with Upjohn.